Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Inflammatory eye disorders
How do you manage a patient with idiopathic bilateral anterior uveitis who is well controlled on Acthar Gel but is planning pregnancy?
Would you recommend transitioning to a TNF inhibitor?
Related Questions
How would you approach the management of dry corneal melt in a patient requiring high dose systemic steroids and no apparent underlying systemic autoimmune disease?
When would you consider discontinuing immunosuppressive treatment in a quiescent uveitis patient without systemic manifestations of inflammation?
How often do you recommend ophthalmologic screening exams for patients with sarcoidosis?
Do you continue TNF inhibitors in patients with a new diagnosis of CLL?
What is your treatment approach for bilateral peripheral ulcerative keratitis that has been resistant to topical treatment in a patient with negative infectious and autoimmune workup?
How do you approach sequentially tapering combination therapy (i.e., IVIG, mycophenolate, rituximab) for dermatomyositis that is in remission?
What were your top takeaways in SLE from ACR Convergence 2025?
Is there any benefit to the use of low dose radiation in patients with osteoarthritis who have already undergone joint replacement?
When evaluating a patient with IgG4-related disease, are there particular exposures or risk factors you routinely ask about during the history to help identify potential contributors?
When trying to increase infliximab for active disease (inflammatory arthritis or sarcoidosis), do you prefer to increase dosage or reduce frequency between doses?